Comparison of biochemical markers of bone turnover in Paget disease treated with pamidronate and a proposed model for the relationships between measurements of the different forms of pyridinoline cross-links

Journal of Bone and Mineral Research

Volumn 11, Issue 8, 1996, Pages 1176-1184

  Randall, A G ^a   Kent, G N ^a   Garcia Webb, P ^b   Bhagat, C I ^a   Pearce, D J ^a   Gutteridge, D H ^c   Prince, R L ^c   Stewart, G ^d   Stuckey, B ^c   Will, R K ^e   Retallack, R W ^c   Price, R I ^c   Ward, L ^c  

^a Western Australian Centre for Pathology and Medical Research   (Australia)

^b ST JOHN OF GOD HOSPITAL   (Australia)

^c PATHWEST LABORATORY MEDICINE   (Australia)

^d FREMANTLE HOSPITAL   (Australia)

^e ROYAL PERTH HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; HYDROXYPROLINE; PAMIDRONIC ACID;

ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BONE REMODELING; BONE TURNOVER; CONTROLLED STUDY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; PAGET BONE DISEASE; URINALYSIS;

EID: 10144263922     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1002/jbmr.5650110817     Document Type: Article

References (28)

1. Delmas PD 1993 Biochemical markers of bone turnover. J Bone Miner Res 8:s549-s555.
2. Seibel MJ, Robins SP, Bilezikian JP 1992 Urinary pyridinium crosslinks of collagen-specific markers of bone resorption in metabolic bone disease. Trends Endocrinol Metab 3:263-270.
3. Colwell A, Eastell R, Assiri AMA, Russell RGG 1990 Effect of diet on deoxypyridinoline excretion. In: Christiansen C, Overgaard K (eds.) Osteoporosis 1990. Osteopress, Copenhagen, Denmark, pp. 590-591.
4. Eyre D 1995 The specificity of collagen cross-links as markers of bone and connective tissue degradation. Acta Orthoped Scand (in press).
5. Melkko J, Niemi S, Risteli L, Risteli J 1990 Radio-immunoassay for the carboxyterminal propeptide of human type I procollagen. Clin Chem 36:1328-1332.
6. Deftos L 1991 Bone protein and peptide assays in the diagnosis and management of skeletal disease. Clin Chem 37:1143-1148.
7. Delaise JM, Vaes G 1992 Mechanism of mineral solubilization and matrix degradation in osteoclastic bone resorption. In: Rifkin BR, Gay CV (eds.) Biology and Physiology of the Osteoclast. CRC Press, Boca Baton, FL, U.S.A., pp. 289-314.
8. Wucherpfennig AL, Yi-Ping L, Stetler-Stevenson WG, Rosenberg AE, Stashenko P 1994 Expression of 92kD type IV collagenase/gelatinase B in human osteoclasts. J Bone Miner Res 9:549-556.
9. Hamdy N 1993 Role of bisphosphonates in metabolic bone diseases. Trends Endocrinol Metab 4:19-25.
10. Fenton A, Gutteridge DH, Kent GN, Price RI, Retallack RW, Bhagat CI, Worth GK, Thompson RI, Watson IG, Barry-Walsh C, Matz LR 1991 Intravenous aminobisphosphonate in Paget's disease: Clinical, biochemical, histomorphometric, and radiological responses. Clin Endocrinol 34:197-204.
11. Kivirikko KI, Laitenen O, Prockop DJ 1967 Modifications of a specific assay for hydroxyproline in urine. Anal Biochem 19:249-255.
12. Black D, Duncan A, Robins P 1988 Quantitative analysis of the pyridinium crosslinks of collagen in urine using ion-paired reverse-phase high-performance liquid chromatography. Anal Biochem 169:197-203.
13. Colwell A, Russell RGG, Eastell R 1993 Factors affecting the assay of the urinary 3-hydroxypyridinium crosslinks of collagen as markers of bone resorption. Eur J Clin Invest 23:341-349.
14. Pratt DA, Daniloff Y, Duncan A, Robins SP 1992 Automated analysis of the pyridinium crosslinks of collagen in tissue and urine using solid-phase extraction and reversed-phase high-performance chromatography. Anal Biochem 207:168-175.
15. Blumsohm A, Naylor K, Assiri A, Eastell R 1995 Different responses of biochemical markers of bone resorption to bisphosphonate therapy in Paget's disease. Clin Chem 41:1592-1598.
16. Alvarez L, Guanabens N, Peris P, Monegal A, Bedini JL, Deulofeu R, Martinez De Osaba M, Munoz-Gomez J, Rivera-Fillat F, Ballesta AM 1995 Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease. J Bone Miner Res 10:458-465.
17. Kaddam I, Iqbal S, Holland S, Wong M, Manning D 1994 Comparison of serum osteocalcin with total and bone specific alkaline phosphatase and urinary hydroxyproline: Creatinine ratio in patients with Paget's disease of bone. Ann Clin Biochem 31:327-330.
18. Ebeling PR, Peterson JM, Riggs BL 1992 Utility of type I procollagen propeptide assays for assessing abnormalities in metabolic bone diseases. J Bone Miner Res 7:1243-1250.
19. Papapoulos S, Frolich M, Muddle H, Harinck H, Berg H, Bijvoet O 1987 Serum osteocalcin in Paget's disease of bone: Basal concentrations and response to bisphosphonate treatment. J Clin Endocrinol Metab 65:89-94.
20. Garnero P, Gineyts E, Riou JP 1994 Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease. J Clin Endocrinol Metab 79:780-785.
21. Gertz B, Shao P, Hanson D, Quan H, Harris S, Genant H, Chesnut C, Eyre D 1994 Monitoring bone resorption in early menopausal women by an immunoassays for cross-linked collagen peptides in urine. J Bone Miner Res 9:135-142.
22. Rosen H, Dresner-Polak R, Moses A, Rosenblatt M, Zeind A, Clemens J, Greenspan S 1994 Specificity of urinary excretion of cross-linked N-telopeptides of type I collagen as a marker of bone turnover. Calcif Tissue Int 54:26-29.
23. Garnero P, Gineyts E, Arbault P, Christiansen C, Delmas P 1995 Different effects of bisphosphonate and estrogen therapy on peptide-bound bone crosslink excretion. J Bone Miner Res 10:641-649.
24. Garnero P, Shih W, Gineyts E, Karpf B, Delmas P 1994 Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 79:1693-1700.
25. Hanson DA, Weis MA, Bollen AM, Maslan SL, Singer FR, Eyre DR 1992 A specific immunoassay for monitoring human bone resorption: Quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res 7:1251-1258.
26. Risteli J, Elomaa I, Niemi S, Novamo A, Risteli L 1993 Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: A new serum marker of bone collagen degradation. Clin Chem 39:635-640.
27. Seyedin S, Kung V, Daniloff Y, Hesley R, Gomez B, Nielsen L, Rosen H, Zuk R 1993 Immunoassay for urinary pyridinoline: The new marker of bone resorption. J Bone Miner Res 8:635-641.
28. Seibel MJ, Woitge H, Scheidt-Nave C, Leidig-Bruckner G, Nicol P, Ziegler R 1994 Urinary hydroxypyridinium crosslinks of collagen in population-based screening for overt vertebral osteoporosis: Results of a private study. J Bone Miner Res 9:1433-1440.